



## GLAUKOS CORPORATION NAMED TO THE WALL STREET JOURNAL'S THIRD ANNUAL "THE NEXT BIG THING" LIST

2012-09-27

Company Named Among 50 Most Promising Venture-Backed Companies

LAGUNA HILLS, CA – September 27, 2012 – Glaukos Corporation (Glaukos) has been named to The Wall Street Journal's 2012 The Next Big Thing list, which seeks to identify and rank venture-backed companies across all industries that have the capital, executive experience and investor know-how to succeed. Glaukos achieved a final ranking at number seven this year and a selection as the nation's highest ranking health-care start-up company. This final WSJ ranking represents the second consecutive selection for Glaukos to the nation's top 50 start-up company finalist list. Glaukos was selected from a 2012 pool of nearly 6,000 businesses and ranked by proprietary data from Dow Jones' News Corp VentureSource.

"We are honored to be selected to this finalist list of elite companies and as the nation's highest ranking health-care start-up company" said Thomas W. Burns, President & CEO of Glaukos Corporation. "The ranking is a testament to the strength of our executive team and Board of Directors and recognition of our decade-long corporate development and fundraising effort to deliver the new MIGS (Micro-Invasive Glaucoma Surgery) market class to ophthalmology".

To date, Glaukos has raised \$126 million in enterprise capital to develop three generations of trabecular bypass and suprachoroidal microstent devices for the treatment of the full range of glaucoma disease.

"The Next Big Thing" is an annual ranking published by The Wall Street Journal. To be eligible for the ranking, a company must be based in the U.S., have raised an equity round of financing in the most recent three years and be valued at \$1 billion or less. The ranking was calculated by applying a set of four financial criteria: the track records of success for both a company's founders and management; track records for the investors on its board; the amount of capital raised in the last three years; and the percentage change in a company's valuation in the last year. Dow Jones VentureWire reporters and editors also provided their perspective and expertise beyond the numbers.

To view "The Next Big Thing" ranking,

visit: <http://online.wsj.com/article/SB10000872396390444813104578018940187057924.html-project=NBT092012%26articleTabs=interactive> **About Dow Jones**

Dow Jones & Company is a global provider of news and business information and a developer of technology to deliver content to consumers and organizations across multiple platforms. Dow Jones produces newspapers, newswires, web sites, apps, newsletters, magazines, proprietary databases, conferences, radio and video. Its premier brands include The Wall Street Journal, Dow Jones Newswires, Factiva, Barron's, MarketWatch, SmartMoney and All Things D. Its information services combine technology with news and data to support business decision-making. The company pioneered the first successful paid online news site and its industry leading innovation enables it to serve customers wherever they may be, via the Web, mobile devices and tablets. The Dow Jones Local Media Group publishes community newspapers, Web sites and other products in six U.S. states. Dow Jones & Company ([www.dowjones.com](http://www.dowjones.com)) is a news corporation company (NASDAQ: NWS) (NASDAQ: NWSA) (ASX: NWS) (ASX: NWSLV) ([www.newscorp.com](http://www.newscorp.com)).

### **About Glaukos Corporation**

Glaukos Corporation is a privately-held ophthalmic company located in Laguna Hills, California, that is dedicated to researching and developing micro-technologies to improve glaucoma therapy. The company has developed a portfolio of microstent devices to treat glaucoma, including the iStent Trabecular Micro-Bypass stent, the first and only FDA-approved device for the treatment of mild-to-moderate open-angle glaucoma in conjunction with cataract surgery.